Evidence map›Paper›PMID 34879421›Full record

ReviewHamostaseologie2022

Platelet Dysregulation in the Pathobiology of COVID-19.

Rebecca A Mellema, Jacob Crandell, Aaron C Petrey

Open access · bronzeAbstract readReview
In one paragraph

Review in Hamostaseologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rebecca A MellemaDivision of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah, United States.
Jacob CrandellMolecular Medicine Program, University of Utah, Salt Lake City, Utah, United States.
Aaron C PetreyDivision of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah, United States.
University of Utah · US

Funding

The Role of Layilin as a Novel Regulator of Platelet Activation and ThromboinflammationR01HL167919 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Aaron Christopher Petrey · 2023 to 2026
$2.6M
Platelet-hyaluronan interactions as regulators of inflammation and thrombosisR00HL135265 · NHLBI · UNIVERSITY OF UTAH · PI PETREY, AARON CHRISTOPHER · 2020 to 2022
$747k
NHLBI NIH HHS R00 HL135265NHLBI NIH HHS R01 HL167919
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) encompasses a broad spectrum of clinical manifestations caused by infection with severe acute respiratory syndrome coronavirus 2.Patients with severe disease present with hyperinflammation which can affect multiple organs which often include observations of microvascular and macrovascular thrombi. COVID-19 is increasingly recognized as a thromboinflammatory disease where alterations of both coagulation and platelets are closely linked to mortality and clinical outcomes. Although platelets are most well known as central mediators of hemostasis, they possess chemotactic molecules, cytokines, and adhesion molecules that are now appreciated as playing an important role in the regulation of immune response. This review summarizes the current knowledge of platelet alterations observed in the context of COVID-19 and their impact upon disease pathobiology.

Indexed as

COVID-19ThrombosisBlood PlateletsHemostasisHumansSARS-CoV-2

Identifiers

PMID34879421
PMCPMC11949001
OpenAlexW4200151701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.